NCT03330106

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Millennium Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to characterize the effects of 25 and 50 milligram per square meter (mg/m\^2) pevonedistat on the Fridericia corrected QT interval (QTcF) of the electrocardiogram (ECG).

Detailed description

The drug being tested in this study is called pevonedistat. Pevonedistat in combination with standard of care will be used to treat participants who have advanced solid tumors. This study will assess the effects of pevonedistat on the QTc interval in participants with advanced solid tumors. The study will enroll approximately 45 participants. The study will be conducted in two Parts: Part A and Part B. Part A will have a 2-way crossover design and will involve the collection of triplicate ECGs. In Part A, participants will be randomly assigned to one of the two treatment groups as follow: * Pevonedistat 25 mg/m\^2 + Pevonedistat 50 mg/m\^2 * Pevonedistat 50 mg/m\^2 + Pevonedistat 25 mg/m\^2 Eligible participants from Part A will continue treatment in optional Part B with pevonedistat in combination with SoC, docetaxel or carboplatin plus paclitaxel. The investigator will decide which pevonedistat combination a participant will receive. * Pevonedistat 25 mg/m\^2 + Docetaxel * Pevonedistat 20 mg/m\^2 + Carboplatin + Paclitaxel This multi-center trial will be conducted in the United States. The overall time to participate in this study is 9.6 months. Participants will make a final visit to the clinic 30 days after receiving their last dose of study drug for a follow-up assessment.

Conditions

• Advanced Solid Neoplasm

Interventions

Type	Name	Description
DRUG	Pevonedistat	Pevonedistat intravenous infusion.
DRUG	Docetaxel	Docetaxel intravenous infusion.
DRUG	Carboplatin	Carboplatin intravenous infusion.
DRUG	Paclitaxel	Paclitaxel intravenous infusion.

Timeline

• Start date: 2017-11-15
• Primary completion: 2019-01-07
• Completion: 2021-06-21
• First posted: 2017-11-06
• Last updated: 2023-03-28
• Results posted: 2023-03-28

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study